Nothing Special   »   [go: up one dir, main page]

AU5030298A - Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion - Google Patents

Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion

Info

Publication number
AU5030298A
AU5030298A AU50302/98A AU5030298A AU5030298A AU 5030298 A AU5030298 A AU 5030298A AU 50302/98 A AU50302/98 A AU 50302/98A AU 5030298 A AU5030298 A AU 5030298A AU 5030298 A AU5030298 A AU 5030298A
Authority
AU
Australia
Prior art keywords
tnf
alpha
overproduction
mammal
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50302/98A
Inventor
Roy A Black
Jeffrey N. Fitzner
Paul R Sleath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU5030298A publication Critical patent/AU5030298A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU50302/98A 1993-08-23 1998-01-06 Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion Abandoned AU5030298A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US110601 1993-08-23
US18301994A 1994-01-18 1994-01-18
US183019 1994-01-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU75694/94A Division AU687436B2 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion

Publications (1)

Publication Number Publication Date
AU5030298A true AU5030298A (en) 1998-03-05

Family

ID=26808203

Family Applications (2)

Application Number Title Priority Date Filing Date
AU75694/94A Ceased AU687436B2 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion
AU50302/98A Abandoned AU5030298A (en) 1993-08-23 1998-01-06 Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU75694/94A Ceased AU687436B2 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion

Country Status (8)

Country Link
EP (1) EP0715619A4 (en)
JP (1) JPH09503201A (en)
AU (2) AU687436B2 (en)
CA (1) CA2170158A1 (en)
FI (1) FI960803A (en)
NO (1) NO960723D0 (en)
NZ (1) NZ271893A (en)
WO (1) WO1995006031A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193978A (en) * 1994-10-05 1998-09-23 奇罗斯恩有限公司 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
AU706064B2 (en) * 1995-05-10 1999-06-10 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
WO1997009420A2 (en) * 1995-09-05 1997-03-13 Celltech Therapeutics Limited Dna sequences coding for a human metalloproteinase and variants thereof
ATE229972T1 (en) * 1995-10-05 2003-01-15 Darwin Discovery Ltd SULFUR SUBSTITUTED PEPTIDES AS INHIBITORS FOR METALLOPROTEINASES AND TNF RELEASE
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
AU711804B2 (en) 1995-11-23 1999-10-21 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
EP0925278B1 (en) 1996-09-10 2002-07-17 British Biotech Pharmaceuticals Limited Cytostatic hydroxamic acid derivatives
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
JP2002516634A (en) * 1997-06-18 2002-06-04 ザ ロックフェラー ユニヴァーシティ Methods of identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
JP2002525302A (en) * 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー Method of treating hair loss using ketoamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
CN1320028A (en) * 1998-09-30 2001-10-31 宝洁公司 Method of treating hair loss using sulfonamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
AU2436600A (en) * 1999-01-13 2000-08-01 Jomaa Pharmaka Gmbh Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
WO2002028829A2 (en) * 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
CN113194954A (en) 2018-10-04 2021-07-30 国家医疗保健研究所 EGFR inhibitors for the treatment of keratoderma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870700065A (en) * 1984-12-19 1987-02-28 아놀드 자일러, 에른스트 알테르 Novel Carbonic Acid Ester
FR2609289B1 (en) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives

Also Published As

Publication number Publication date
NO960723L (en) 1996-02-23
AU7569494A (en) 1995-03-21
CA2170158A1 (en) 1995-03-02
EP0715619A1 (en) 1996-06-12
NZ271893A (en) 1997-11-24
FI960803A (en) 1996-04-22
WO1995006031A1 (en) 1995-03-02
NO960723D0 (en) 1996-02-23
JPH09503201A (en) 1997-03-31
AU687436B2 (en) 1998-02-26
EP0715619A4 (en) 1997-03-19
FI960803A0 (en) 1996-02-22

Similar Documents

Publication Publication Date Title
AU5030298A (en) Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion
AU695664B2 (en) Method for treating cardiac inflammatory disease
AU639500B2 (en) Method for production of acrylic acid
AU7023191A (en) Method for fabrication of implantable electrode
AU3067995A (en) Method for treatment of sleep apnea
IL111257A0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
EP0617457A3 (en) Method for production of wafer.
AU3198699A (en) Method for the treatment of joint diseases characterized by unwanted pannus
AU2103295A (en) Methods for the treatment of thrombosis
AU4891696A (en) Method for production of alkylhalosilanes
AU1111492A (en) Method of treating type i diabetes
AU7626991A (en) Combination of pravastatin and fibric acid derivative, and method for treating dyslipidemia using such combination
AU3579195A (en) Process for manufacturing clavulanic acid salt
AU1727499A (en) Method for treating fibroproliferative disorders by inhibitors of protein hydroxylation
AU2685892A (en) Method of treating blood
AU8166191A (en) Method for treatment of bone wasting diseases
AU6153094A (en) Plant tissue culture method for taxol production
AU6973294A (en) Method for treatment of a piece
AU6771190A (en) Method for treatment of waste water from (meth)acrylic acid production plant
AU5831800A (en) Method for the control of the manufacturing process of polyols
AU8113091A (en) Method of treatment of allergic conjunctivitis
AU8752991A (en) Method of treating auto-immune diseases using gallium compounds
AU2668201A (en) Method for the production of optically active cyanohydrins using r-oxynitrilase
AU1393801A (en) Method for the treatment and/or prophylaxis of diseases caused by il-12
AU1108101A (en) Method of treating plants

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application